Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia.

Trial Profile

Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 (Primary)
  • Indications Lymphoid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2007 Planned end date added (Oct 2005) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top